Browse the evidence

GLP-1 receptor agonists (semaglutide, liraglutide, dulaglutide) reduce Major Adverse Cardiovascular Events (MACE) and all-cause mortality in patients with Type 2 Diabetes and established CVD, primarily through weight loss, blood pressure reduction, and anti-inflammatory effects.

If you have Type 2 Diabetes and heart disease, GLP-1 agonists (like semaglutide or liraglutide) are highly effective at reducing the risk of heart attacks, strokes, and death. They work by mimicking a gut hormone to lower blood sugar, promote weight loss, and reduce blood pressure. While they require injections and may cause temporary stomach issues, the heart protection benefits are substantial and well-documented.

Obesity increases the risk of various cancers (e.g., breast, colorectal, liver) through mechanisms involving chronic inflammation, oxidative stress, and altered adipokine secretion (e.g., increased leptin, decreased adiponectin).

Obesity increases your risk for several types of cancer through biological processes like inflammation and hormone imbalance. Maintaining a healthy weight can reduce this risk by mitigating these specific biological factors.

Obesity contributes to cardiovascular disease (CVD) through mechanisms including adipose tissue dysfunction, ectopic fat deposition, and altered adipokine secretion (e.g., increased leptin, decreased adiponectin), leading to hypertension, atherosclerosis, and heart failure.

Obesity increases your risk for heart disease and stroke through biological processes like inflammation and hormone imbalance. Maintaining a healthy weight can reduce this risk by mitigating these specific biological factors.

Obesity is a primary driver of Heart Failure with Preserved Ejection Fraction (HFpEF) through cardiometabolic mechanisms including systemic inflammation, lipotoxicity, and metabolic remodeling, rather than being merely a comorbidity.

If you have HFpEF and obesity, your body's metabolism and inflammation are likely driving your heart condition. This is not just about 'being overweight' but involves complex biological changes like fat toxicity and inflammation. Managing obesity through weight loss interventions (like GLP-1 agonists or lifestyle changes) can target these root causes and improve heart health.

Discontinuation of semaglutide or tirzepatide leads to significant weight regain, indicating that these therapies require long-term use to maintain metabolic benefits.

If you stop taking semaglutide or tirzepatide, you will likely regain most of the weight you lost. These drugs treat obesity and diabetes as chronic conditions, meaning they are meant to be taken long-term to maintain the health benefits. Stopping them reverses the progress made.

Intermittent fasting (IMF) and daily caloric restriction (DCR) produce equivalent weight loss when matched for energy deficit and delivered with guideline-based behavioral support and physical activity prescriptions.

To lose weight effectively, you can choose either daily calorie restriction or intermittent fasting, but the key is consistency and support. Ensure your total weekly energy deficit is similar regardless of the method. Crucially, engage in a structured behavioral support program that includes regular check-ins, goal setting, and physical activity (aiming for 300 minutes of moderate exercise per week). This structured approach is more important than the specific timing of your meals for long-term success.

There is no significant difference in the reduction of absolute fat mass (kg) or waist circumference between low-carbohydrate and low-fat diets.

While LCDs may lower BMI and body fat percentage more than LFDs, they do not necessarily reduce absolute fat mass (kg) or waist circumference more effectively. If waist circumference is your primary goal, either diet may be equally effective.

Semaglutide treatment is associated with a significantly higher incidence of gastrointestinal adverse events (nausea, diarrhea, vomiting, constipation) compared to placebo, though these are mostly mild to moderate.

Be prepared for gastrointestinal side effects like nausea and diarrhea, especially when starting or increasing the dose. These are common but usually mild and temporary. Titration helps manage them.

High body-mass index (BMI) is a significant metabolic risk factor with increasing exposure rates (1.8% annually) and a 15.7% rise in age-standardized DALY rates from 2000 to 2021.

High BMI is a significant metabolic risk factor with increasing exposure rates. Addressing high BMI is crucial for long-term health.

Sarcopenic obesity is defined by the co-existence of excess adiposity and low skeletal muscle mass/function, requiring a two-step diagnostic algorithm of screening followed by functional and body composition assessment.

To identify sarcopenic obesity, first screen for high BMI or waist circumference. If positive, test muscle function (e.g., handgrip strength). If function is low, assess body composition (DXA or BIA) to confirm low muscle mass relative to fat. This two-step process ensures accurate diagnosis without unnecessary expensive testing for everyone.

GLP-1 receptor agonists (GLP-1RAs) effectively treat type 2 diabetes and obesity by mimicking endogenous GLP-1 to stimulate glucose-dependent insulin secretion, suppress glucagon, delay gastric emptying, and reduce appetite via central nervous system signaling.

GLP-1 medications are highly effective for managing type 2 diabetes and obesity. They work by mimicking a natural hormone to boost insulin when needed, lower blood sugar, slow digestion, and reduce hunger. While they often require injections, many are now available as once-weekly shots or even pills. Side effects like nausea are common at first but usually fade. They are not for type 1 diabetes. Always combine with diet and exercise.

Metabolic and bariatric surgery (MBS) is recommended for individuals with BMI >35 kg/m2 regardless of comorbidity status, and for those with BMI 30-34.9 kg/m2 who have metabolic disease or fail nonsurgical treatments.

If your BMI is over 35, surgery is a recommended first-line treatment option, not just a last resort. If your BMI is between 30 and 35, you should still consider surgery, especially if you have diabetes or other metabolic issues, or if lifestyle changes haven't worked. For Asian individuals, the thresholds are lower (BMI >27.5 for surgery consideration).

Automated insulin delivery (AID) systems significantly improve glycemic control in people with type 1 diabetes by increasing time in range and reducing hypoglycemia compared to other therapies.

If you have Type 1 Diabetes, an Automated Insulin Delivery (AID) system is a highly effective tool to improve your blood sugar control. It automatically adjusts your insulin based on real-time glucose readings, helping you spend more time in your target range and less time in dangerous low or high states. While it still requires you to count carbs and announce meals, the system handles the fine-tuning. Ensure you receive proper training and support from your healthcare provider to get the most benefit and address any access barriers.

Global prevalence of vitamin D deficiency (serum 25(OH)D <30 nmol/L) is 15.7%, with significantly higher rates in high-latitude regions, winter-spring seasons, females, and lower-middle-income countries.

Vitamin D deficiency is a global issue affecting roughly 16% of adults, with higher risks in winter, at high latitudes, and for women. To mitigate this, prioritize Vitamin D supplementation or consumption of fortified foods, especially if you live in northern regions, wear covering clothing, or have limited sun exposure. Regular testing of serum 25(OH)D levels is recommended to ensure adequacy.

Ketone bodies (KBs) serve as an efficient energy source that bypasses glycolysis, promoting mitochondrial oxidative metabolism and reducing oxidative stress.

Your brain can run efficiently on ketone bodies produced by the ketogenic diet. These molecules enter the Krebs cycle directly, bypassing the slower glycolytic pathway, which enhances mitochondrial energy production and reduces oxidative stress. This metabolic shift is central to the diet's benefits for neurological and metabolic health.

Insulin resistance (IR) is a major driver of PCOS pathophysiology, present in 65-95% of women with PCOS, and is independent of and exacerbated by obesity.

Insulin resistance is a core feature of PCOS, affecting most women with the condition, regardless of weight. Managing insulin levels is crucial for treating PCOS symptoms and reducing long-term health risks like type 2 diabetes.

Oral semaglutide (up to 14 mg daily) significantly reduces the risk of major adverse cardiovascular events (MACE) in high-risk patients with type 2 diabetes, specifically those with established atherosclerotic cardiovascular disease or chronic kidney disease.

If you have type 2 diabetes and existing heart disease or kidney issues, taking oral semaglutide (up to 14 mg daily) alongside your standard care significantly lowers your risk of heart attack, stroke, or cardiovascular death compared to a placebo. This benefit is achieved without increasing serious side effects, making it a viable option for cardiovascular risk reduction in this high-risk group.

The health benefits attributed to ellagitannin-rich foods (pomegranates, walnuts) are primarily driven by Urolithin A, but these benefits are conditional on the individual's gut microbiota composition (metabotype).

Eating pomegranates or walnuts is healthy, but your gut bacteria must convert them into Urolithin A for maximum benefit. If you are a 'non-producer' (UM-0), you might not get these specific benefits. Testing your metabotype or using Uro-A supplements can ensure you get the intended effects.

Tirzepatide does not increase the risk of hypoglycemia compared to placebo and has a lower risk compared to basal insulin.

Unlike insulin, Tirzepatide does not increase the risk of low blood sugar (hypoglycemia) when used alone. In fact, it has a lower risk of causing hypoglycemia compared to basal insulin. This makes it a safer option for patients who are concerned about blood sugar lows.

Mitochondrial impairment accelerates epigenetic aging, while enhancing mitochondrial biogenesis slows it, establishing a direct link between mitochondrial function and the rate of epigenetic aging.

Mitochondrial health is a key driver of epigenetic aging. Impairing mitochondria accelerates the epigenetic clock, while boosting mitochondrial biogenesis slows it. This suggests that interventions supporting mitochondrial function (like exercise or specific nutrients) may slow epigenetic aging, independent of DNA repair or telomere length.

Once-weekly subcutaneous semaglutide 2.4 mg reduces the risk of major kidney composite endpoints (including macroalbuminuria and persistent eGFR decline) in patients with overweight/obesity and established cardiovascular disease, regardless of diabetes status.

If you have obesity and heart disease but no diabetes, semaglutide 2.4mg weekly offers significant kidney protection. It reduces the risk of serious kidney events like needing dialysis or developing heavy protein in the urine. While there is a temporary initial dip in kidney filtration numbers, long-term outcomes are better than placebo. This is a standard-of-care option for kidney risk reduction in this specific high-risk group.

Semaglutide 2.4 mg slows the rate of eGFR decline and reduces albuminuria (UACR) in patients with overweight/obesity, with greater benefits observed in those with baseline eGFR <60 ml/min/1.73m².

For patients with existing kidney impairment (eGFR <60), semaglutide not only slows further decline but may actually improve eGFR readings compared to placebo. It also significantly reduces albuminuria (protein in urine), a key marker of kidney stress. This benefit is consistent across subgroups.

High body mass index (BMI > 25 kg/m²) is a major global health risk factor that has caused a more than 2.5-fold increase in global deaths and disability-adjusted life years (DALYs) between 1990 and 2021, with cardiovascular diseases and diabetes being the leading causes of this burden.

High body mass index (BMI) is a major, modifiable risk factor for serious diseases like heart disease, diabetes, and kidney disease. The global burden of disease from high BMI has more than doubled in 30 years. To protect your health, it is crucial to monitor your BMI and work towards maintaining a healthy weight through sustainable lifestyle changes, as high BMI significantly increases your risk of premature death and disability.

Tirzepatide treatment is associated with a higher incidence of gastrointestinal adverse events (nausea, diarrhea, vomiting) compared to placebo and insulin, and slightly higher than GLP-1 RAs, though serious adverse events are not significantly different from placebo.

Expect gastrointestinal side effects like nausea, diarrhea, or vomiting, especially when starting or increasing the dose. These are usually mild and go away. Serious side effects (like pancreatitis or heart issues) did not show a statistically significant increase compared to placebo in this analysis. Monitor your symptoms and report severe or persistent issues to your doctor.